Predictive biomarkers for the outcome of vaccination of five therapeutic epitope peptides for colorectal cancer

Shoichi Hazama, Hiroko Takenouchi, Ryouichi Tsunedomi, Michihisa Iida, Nobuaki Suzuki, Norio Iizuka, Yuka Inoue, Kazuhiko Sakamoto, Mitsuhiro Nakao, Yoshitaro Shindo, Shinsuke Kanekiyo, Yukio Tokumitsu, Kiyoshi Yoshimura, Noriko Maeda, Kazunari Maeda, Yoshinari Maeda, Hiroto Matsui, Shigefumi Yoshino, Yusuke Nakamura, Yusuke FujitaYoshihiko Hamamoto, Masato Okamoto, Tomonobu Fujita, Yutaka Kawakami, Masaaki Oka

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background: We previously reported a phase I study of a cancer vaccine using five novel HLA-A∗2402-restricted peptides, and demonstrated the safety and the promising potential of our five-peptide cocktail for advanced colorectal cancer. The objective of this analysis was to investigate predictive biomarkers for the prior selection of patients who are likely to have clinical benefit from such therapy. Patients and Methods: Seventeen patients with colorectal cancer who were treated with the five peptides underwent a complete blood count, serum chemistry tests and enzyme-linked ImmunoSpot assay before the treatment as predictive markers of high reactivity to the peptides. Results: Interleukin-6 level was a significant predictor for overall survival of patients treated with the peptide cocktail (p=0.017). A high neutrophil/lymphocyte ratio was likely to have some association with the poor induction of peptide-specific immune reaction. Conclusion: Interleukin-6 level might be a good predictive biomarker for clinical benefit of patients treated with this peptide vaccine.

Original languageEnglish
Pages (from-to)4201-4206
Number of pages6
JournalAnticancer Research
Volume34
Issue number8
Publication statusPublished - 2014 Aug 1

Fingerprint

Epitopes
Colorectal Neoplasms
Vaccination
Biomarkers
Peptides
Interleukin-6
Therapeutics
Enzyme-Linked Immunospot Assay
Cancer Vaccines
Subunit Vaccines
Blood Cell Count
Patient Selection
Neutrophils
Lymphocytes
Safety
Survival
Serum

Keywords

  • Colorectal cancer
  • Peptide vaccine
  • Predictive biomarker
  • Prognosis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Hazama, S., Takenouchi, H., Tsunedomi, R., Iida, M., Suzuki, N., Iizuka, N., ... Oka, M. (2014). Predictive biomarkers for the outcome of vaccination of five therapeutic epitope peptides for colorectal cancer. Anticancer Research, 34(8), 4201-4206.

Predictive biomarkers for the outcome of vaccination of five therapeutic epitope peptides for colorectal cancer. / Hazama, Shoichi; Takenouchi, Hiroko; Tsunedomi, Ryouichi; Iida, Michihisa; Suzuki, Nobuaki; Iizuka, Norio; Inoue, Yuka; Sakamoto, Kazuhiko; Nakao, Mitsuhiro; Shindo, Yoshitaro; Kanekiyo, Shinsuke; Tokumitsu, Yukio; Yoshimura, Kiyoshi; Maeda, Noriko; Maeda, Kazunari; Maeda, Yoshinari; Matsui, Hiroto; Yoshino, Shigefumi; Nakamura, Yusuke; Fujita, Yusuke; Hamamoto, Yoshihiko; Okamoto, Masato; Fujita, Tomonobu; Kawakami, Yutaka; Oka, Masaaki.

In: Anticancer Research, Vol. 34, No. 8, 01.08.2014, p. 4201-4206.

Research output: Contribution to journalArticle

Hazama, S, Takenouchi, H, Tsunedomi, R, Iida, M, Suzuki, N, Iizuka, N, Inoue, Y, Sakamoto, K, Nakao, M, Shindo, Y, Kanekiyo, S, Tokumitsu, Y, Yoshimura, K, Maeda, N, Maeda, K, Maeda, Y, Matsui, H, Yoshino, S, Nakamura, Y, Fujita, Y, Hamamoto, Y, Okamoto, M, Fujita, T, Kawakami, Y & Oka, M 2014, 'Predictive biomarkers for the outcome of vaccination of five therapeutic epitope peptides for colorectal cancer', Anticancer Research, vol. 34, no. 8, pp. 4201-4206.
Hazama S, Takenouchi H, Tsunedomi R, Iida M, Suzuki N, Iizuka N et al. Predictive biomarkers for the outcome of vaccination of five therapeutic epitope peptides for colorectal cancer. Anticancer Research. 2014 Aug 1;34(8):4201-4206.
Hazama, Shoichi ; Takenouchi, Hiroko ; Tsunedomi, Ryouichi ; Iida, Michihisa ; Suzuki, Nobuaki ; Iizuka, Norio ; Inoue, Yuka ; Sakamoto, Kazuhiko ; Nakao, Mitsuhiro ; Shindo, Yoshitaro ; Kanekiyo, Shinsuke ; Tokumitsu, Yukio ; Yoshimura, Kiyoshi ; Maeda, Noriko ; Maeda, Kazunari ; Maeda, Yoshinari ; Matsui, Hiroto ; Yoshino, Shigefumi ; Nakamura, Yusuke ; Fujita, Yusuke ; Hamamoto, Yoshihiko ; Okamoto, Masato ; Fujita, Tomonobu ; Kawakami, Yutaka ; Oka, Masaaki. / Predictive biomarkers for the outcome of vaccination of five therapeutic epitope peptides for colorectal cancer. In: Anticancer Research. 2014 ; Vol. 34, No. 8. pp. 4201-4206.
@article{3db5e56645624cd5a1c6215f930f8ba1,
title = "Predictive biomarkers for the outcome of vaccination of five therapeutic epitope peptides for colorectal cancer",
abstract = "Background: We previously reported a phase I study of a cancer vaccine using five novel HLA-A∗2402-restricted peptides, and demonstrated the safety and the promising potential of our five-peptide cocktail for advanced colorectal cancer. The objective of this analysis was to investigate predictive biomarkers for the prior selection of patients who are likely to have clinical benefit from such therapy. Patients and Methods: Seventeen patients with colorectal cancer who were treated with the five peptides underwent a complete blood count, serum chemistry tests and enzyme-linked ImmunoSpot assay before the treatment as predictive markers of high reactivity to the peptides. Results: Interleukin-6 level was a significant predictor for overall survival of patients treated with the peptide cocktail (p=0.017). A high neutrophil/lymphocyte ratio was likely to have some association with the poor induction of peptide-specific immune reaction. Conclusion: Interleukin-6 level might be a good predictive biomarker for clinical benefit of patients treated with this peptide vaccine.",
keywords = "Colorectal cancer, Peptide vaccine, Predictive biomarker, Prognosis",
author = "Shoichi Hazama and Hiroko Takenouchi and Ryouichi Tsunedomi and Michihisa Iida and Nobuaki Suzuki and Norio Iizuka and Yuka Inoue and Kazuhiko Sakamoto and Mitsuhiro Nakao and Yoshitaro Shindo and Shinsuke Kanekiyo and Yukio Tokumitsu and Kiyoshi Yoshimura and Noriko Maeda and Kazunari Maeda and Yoshinari Maeda and Hiroto Matsui and Shigefumi Yoshino and Yusuke Nakamura and Yusuke Fujita and Yoshihiko Hamamoto and Masato Okamoto and Tomonobu Fujita and Yutaka Kawakami and Masaaki Oka",
year = "2014",
month = "8",
day = "1",
language = "English",
volume = "34",
pages = "4201--4206",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "8",

}

TY - JOUR

T1 - Predictive biomarkers for the outcome of vaccination of five therapeutic epitope peptides for colorectal cancer

AU - Hazama, Shoichi

AU - Takenouchi, Hiroko

AU - Tsunedomi, Ryouichi

AU - Iida, Michihisa

AU - Suzuki, Nobuaki

AU - Iizuka, Norio

AU - Inoue, Yuka

AU - Sakamoto, Kazuhiko

AU - Nakao, Mitsuhiro

AU - Shindo, Yoshitaro

AU - Kanekiyo, Shinsuke

AU - Tokumitsu, Yukio

AU - Yoshimura, Kiyoshi

AU - Maeda, Noriko

AU - Maeda, Kazunari

AU - Maeda, Yoshinari

AU - Matsui, Hiroto

AU - Yoshino, Shigefumi

AU - Nakamura, Yusuke

AU - Fujita, Yusuke

AU - Hamamoto, Yoshihiko

AU - Okamoto, Masato

AU - Fujita, Tomonobu

AU - Kawakami, Yutaka

AU - Oka, Masaaki

PY - 2014/8/1

Y1 - 2014/8/1

N2 - Background: We previously reported a phase I study of a cancer vaccine using five novel HLA-A∗2402-restricted peptides, and demonstrated the safety and the promising potential of our five-peptide cocktail for advanced colorectal cancer. The objective of this analysis was to investigate predictive biomarkers for the prior selection of patients who are likely to have clinical benefit from such therapy. Patients and Methods: Seventeen patients with colorectal cancer who were treated with the five peptides underwent a complete blood count, serum chemistry tests and enzyme-linked ImmunoSpot assay before the treatment as predictive markers of high reactivity to the peptides. Results: Interleukin-6 level was a significant predictor for overall survival of patients treated with the peptide cocktail (p=0.017). A high neutrophil/lymphocyte ratio was likely to have some association with the poor induction of peptide-specific immune reaction. Conclusion: Interleukin-6 level might be a good predictive biomarker for clinical benefit of patients treated with this peptide vaccine.

AB - Background: We previously reported a phase I study of a cancer vaccine using five novel HLA-A∗2402-restricted peptides, and demonstrated the safety and the promising potential of our five-peptide cocktail for advanced colorectal cancer. The objective of this analysis was to investigate predictive biomarkers for the prior selection of patients who are likely to have clinical benefit from such therapy. Patients and Methods: Seventeen patients with colorectal cancer who were treated with the five peptides underwent a complete blood count, serum chemistry tests and enzyme-linked ImmunoSpot assay before the treatment as predictive markers of high reactivity to the peptides. Results: Interleukin-6 level was a significant predictor for overall survival of patients treated with the peptide cocktail (p=0.017). A high neutrophil/lymphocyte ratio was likely to have some association with the poor induction of peptide-specific immune reaction. Conclusion: Interleukin-6 level might be a good predictive biomarker for clinical benefit of patients treated with this peptide vaccine.

KW - Colorectal cancer

KW - Peptide vaccine

KW - Predictive biomarker

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=84908672347&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908672347&partnerID=8YFLogxK

M3 - Article

C2 - 25075047

AN - SCOPUS:84908672347

VL - 34

SP - 4201

EP - 4206

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 8

ER -